BAT 8006
Alternative Names: BAT-8006Latest Information Update: 06 Jun 2024
At a glance
- Originator Bio-Thera Solutions
- Class Alkaloids; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
Most Recent Events
- 02 Jun 2024 NMPA approves clinical trial application for BAT 8006 in Solid tumours (Combination therapy)
- 02 Jun 2024 Efficacy and adverse events data from a phase I trial in Solid tumors released by Bio-Thera Solutions
- 25 Mar 2024 Rocket Pharmaceuticals receives IND clearance from the US FDA for BAT 8006 for platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer